Stockreport

ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating [Yahoo! Finance]

ARS Pharmaceuticals, Inc.  (SPRY) 
PDF reiterated its Buy rating on ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) with a price target of $30 on the stock. In other news, on December 29, ARS Pharmaceuticals, Inc. [Read more]